PharmaCM CT 2.0 to Help Pharma Manage Multinational Registries
NEW YORK, August 20, 2013 – With the life sciences R&D industry undergoing a “major shift around modernization,” Deloitte Analytics LLC is releasing PharmaCM CT 2.0, a solution that gives pharmaceutical and biotech companies one system for managing the clinical trial application process in both the United States and Europe.
PharmaCM CT 2.0 automates much of the activity involved in initiating clinical trials on the U.S. and European registries and in complying with ongoing disclosure and publishing requirements. It’s an upgrade from PharmaCM CT 1.0 in that it supports the European Clinical Trial Database (EudraCT) in addition to its U.S. counterpart, ClinicalTrials.gov.
“Today’s pharma and biotech companies play on a global stage, so they need solutions that do the same,” said Thomas Wicks, general manager, Deloitte Analytics LLC and PharmaCM business leader. “Using a single platform to manage more of a firm’s global trial activity will reduce time training staff and doing manual procedures.”
According to Matthew Hudes, managing principal, Deloitte Consulting LLP and leader of Deloitte’s biotechnology industry practice, products like PharmaCM CT 2.0 reflect a broader transformation underway working to modernize the R&D process.
“One of the promising trends in life sciences today is how drug and device development is adopting innovative process improvements – techniques that have greatly enhanced productivity in other industries,” said Hudes. “PharmaCM CT 2.0 is an example of how pharma and biotech may be able to utilize these capabilities to substantially improve the R&D process.”
Wicks said PharmaCM CT 2.0’s functionality includes managing disclosure workflows, accepting data from multiple sources and tracking compliance dates. He also noted that it’s updated frequently to reflect regulatory changes.
“This solution harmonizes data across various registries and can significantly reduce the manual labor and IT resources needed in conducting clinical trials from a global perspective,” said Wicks.
Please visit www.pharmacm.com for more information or to schedule a product demonstration.
About Deloitte’s Life Sciences and Health Care Practice
Deloitte’s life sciences and health care practice brings fresh insight to clients and industry stakeholders. Deloitte offers a distinctive menu of professional services delivered in an integrated approach that address many segments of the health plan, health provider and life sciences industries. For more information, visit www.deloitte.com/view/en_US/us/Industries/index.htm
As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.